Abstract
Melissa Rangel, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Atypical ductal lesions of the breast: criteria, significance, and laboratory updates
10.5858/arpa.2018-0221-ra · 2018
Spectrum of atypical ductal hyperplasia (ADH) and ductal carcinoma in-situ (DCIS): diagnostic challenges
10.1053/j.semdp.2024.09.001 · 2024
Breast cancer screening and diagnosis (version 2.2025)
Kept as external metadata until matched
Resource guide: surgical management of benign or high-risk lesions
Kept as external metadata until matched
Upgrade rate of percutaneously diagnosed pure atypical ductal hyperplasia: systematic review and meta-analysis of 6458 lesions
10.1148/radiol.2019190748 · 2020
Development and prospective validation of a risk calculator that predicts a low risk cohort for atypical ductal hyperplasia upstaging to malignancy: evidence for a watch and wait strategy of a high-risk lesion
10.1245/s10434-020-08881-0 · 2020
Implications of the COMET trial for the management of atypical ductal hyperplasia
10.1245/s10434-025-18236-2 · 2026
Is surgical excision of focal atypical ductal hyperplasia warranted? Experience at a tertiary care center
10.1245/s10434-023-13319-4 · 2023
Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy
10.1016/j.breast.2010.06.004 · 2011
Breast Cancer. (Version 5.2025)
Kept as external metadata until matched
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment
10.1016/s0140-6736(24)00425-2 · 2024
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
10.1093/jnci/djr027 · 2011
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
10.1016/s0140-6736(15)01168-x · 2016
Learning to distinguish progressive and non-progressive ductal carcinoma in situ
10.1038/s41568-022-00512-y · 2022
Ductal carcinoma in situ: to treat or not to treat, that is the question
10.1038/s41416-019-0478-6 · 2019
Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)
10.1016/j.breast.2016.09.001 · 2017
Treatment of low-risk ductal carcinoma in situ: is nothing better than something?
10.1016/s1470-2045(16)30367-9 · 2016
Addressing overtreatment of screen detected DCIS; the LORIS trial
10.1016/j.ejca.2015.07.017 · 2015
The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA)
10.1200/jco.2019.37.15_suppl.tps603 · 2019
Active surveillance versus treatment in low-risk DCIS: women’s preferences in the LORD-trial
10.1016/j.ejca.2023.113276 · 2023
Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial
10.1001/jama.2024.26698 · 2025
Long-term safety of observation in selected women following core biopsy diagnosis of atypical ductal hyperplasia
10.1245/s10434-016-5512-9 · 2017
Risk of breast cancer in selected women with atypical ductal hyperplasia who do not undergo surgical excision
10.1097/sla.0000000000004849 · 2022
The target trial framework for causal inference from observational data: why and when is it helpful?
10.7326/annals-24-01871 · 2025
Transparent reporting of observational studies emulating a target trial—the TARGET statement
10.1001/jama.2025.13350 · 2025
Grace periods in comparative effectiveness studies of sustained treatments
10.1093/jrsssa/qnae002 · 2024
The effect of delay of excisional biopsy on upstage rate for atypical ductal hyperplasia, flat epithelial atypia, intraductal papilloma, and radial scar
10.1007/s10549-022-06745-7 · 2022
Active surveillance of atypical ductal hyperplasia of the breast
10.1016/j.clbc.2023.05.008 · 2023
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data
10.2202/1557-4679.1212 · 2010
Methods to estimate the comparative effectiveness of clinical strategies that administer the same intervention at different times
10.1007/s40471-015-0045-5 · 2015
Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses
10.1016/j.jclinepi.2016.04.014 · 2016
How to estimate the effect of treatment duration on survival outcomes using observational data
10.1136/bmj.k182 · 2018
De-mystifying the clone-censor-weight method for causal Research using observational data: a primer for cancer researchers
10.1002/cam4.70461 · 2024
Data-adaptive selection of the propensity score truncation level for inverse-probability–weighted and targeted maximum likelihood estimators of marginal point treatment effects
10.1093/aje/kwac087 · 2022
Constructing inverse probability weights for marginal structural models
10.1093/aje/kwn164 · 2008
Unresolved referenced work
2025
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men
10.1097/00001648-200009000-00012 · 2000
Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study
10.1002/sim.4780091214 · 1990
The parametric g-formula for time-to-event data: intuition and a worked example
10.1097/ede.0000000000000160 · 2014
gfoRmula: an R package for estimating the effects of sustained treatment strategies via the parametric g-formula
10.1016/j.patter.2020.100008 · 2020
Rates of atypical ductal hyperplasia have declined with less use of post-menopausal hormone treatment. Findings from the Breast Cancer Surveillance Consortium
10.1158/1055-9965.epi-09-0745 · doi-reference
Imaging changes and outcomes of patients undergoing active monitoring for ductal carcinoma in situ: seven-year follow-up study
10.1016/j.acra.2023.12.021 · doi-reference
Participation in a high-risk program is associated with a diagnosis of earlier-stage disease among women at increased risk for breast cancer development
10.1245/s10434-024-15633-x · doi-reference
Atypical ductal hyperplasia: interobserver and intraobserver variability
10.1038/modpathol.2011.66 · doi-reference
Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?
10.1245/s10434-012-2575-0 · doi-reference
Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision
10.1309/0gyv4f2lljav4gfn · doi-reference
ACR appropriateness criteria® imaging of ductal carcinoma in situ (DCIS)
10.1016/j.jacr.2025.02.027 · doi-reference
Emulating target trials to study perioperative and critical care interventions with observational data: promise and limitations
10.1097/aln.0000000000005308 · doi-reference
Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review
10.1001/jamanetworkopen.2023.36023 · doi-reference
Conducting observational analyses with the target trial emulation approach: a methodological systematic review
10.1136/bmjopen-2024-086595 · doi-reference
Eighth edition of the AJCC cancer staging manual: breast cancer
10.1245/s10434-018-6486-6 · doi-reference
A structural description of biases that generate immortal time
10.1097/ede.0000000000001808 · doi-reference
A simulation study comparing the performance of time-varying inverse probability weighting and G-computation in survival analysis
10.1093/aje/kwac162 · doi-reference
Evaluating model specification when using the parametric G-formula in the presence of censoring
10.1093/aje/kwad143 · doi-reference